Ikeda M, Taguchi T, Ota K, Furue H, Niitani H, Tsukagoshi S, Ariyoshi Y, Akasaka Y, Ohta J, Suminaga M
Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osakasayama, Japan.
Gan To Kagaku Ryoho. 1992 Sep;19(11):1905-14.
The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies. In this study, ondansetron was given intravenously with mainly a single dose of 4 mg to intervene nausea and vomiting. 1. Efficacy ratio of overall effects on nausea and emesis observed for 24 hours after treatment was 69.8%. 2. No side effect was observed. Laboratory tests showed temporary elevation of serum uric acid level in 1 patient in the group given 4 mg. 3. From these results, it seems that ondansetron, given intravenously after initial vomiting, was highly safe and clinically useful anti-emetic for the treatment of nausea and vomiting associated with anti-cancer drugs.
一项多机构研究对昂丹司琼治疗包括顺铂在内的抗癌药物所致恶心和呕吐的止吐效果、安全性及临床实用性进行了评估，研究对象为患有各种恶性肿瘤的患者。在本研究中，昂丹司琼主要以单次静脉注射4毫克的方式给药，以干预恶心和呕吐。1. 治疗后24小时观察到的对恶心和呕吐的总体有效率为69.8%。2. 未观察到副作用。实验室检查显示，4毫克剂量组中有1名患者血清尿酸水平暂时升高。3. 从这些结果来看，在初次呕吐后静脉注射昂丹司琼似乎是一种治疗抗癌药物相关恶心和呕吐的高度安全且临床有用的止吐药。
